跳至主要内容
临床试验/CTRI/2018/10/016123
CTRI/2018/10/016123已完成2 期

“PRAKRITI- A RISK FACTOR FOR MEDO ROGA (ADIPOSOPATHY): WHO STEPS BASED NIDANATMAKA STUDY AND RANDOMIZED UPASHAYATMAKA (CLINICAL) TRIAL OF TRYUSHANADI GUGGULU AND NAVAKA GUGGULUâ€

NATIONAL INSTITUTE OF AYURVEDA JAIPUR1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2018年5月11日最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
60
试验地点
1
主要终点
patients of both sexes between age group 18 to 60 years of medoroga will be selected for relieving sign and symptoms

研究概览

简要总结

This is an Open label Randomised single centre trial comparing efficacy of ayurvedic drugs Tryushanadi Guggulu and Navaka Guggulu in the management of Medoroga (adiposopathy). Patient of both sexes between age 18 to 60 years of medoroga will be selected for relieving sign and symptoms. 60 clinically diagnosed and confirmed patients will be randomly divided into two groups for administration of trial drugs. In group I, 30 patients will be administered trial drug tryushanadi guggulu in the dose of 1 gm BD orally for 4 weeks.  In group II, 30 patients will be administered trial drug navaka guggulu in the dose of 1 gm BD orally for 4 weeks.All the patients registered for the clinical trial will be asked for any changes in their clinical manifestations and growing feeling of well being. Conclusion- to compare the efficacy of both the drugs.

研究设计

研究类型
Interventional
分配方式
Coin toss, Lottery, toss of dice, shuffling cards etc
盲法
Open Label

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • 1-SUBJECTS OF AGE
  • 60 YEARS. 2-SUBJECTS OF EITHER SEX. 3-SUBJECTS FOUND TO BE SUFFERING WITH MEDOROGA IN THE NIDANATMAKA STUDY ON THE BASIS OF PARAMETERS SUCH AS ADIPOSOPATHY & DYSLIPIDEMIA AS WELL AS THE AYURVEDIC PARAMETERS AND THEREAFTER CONSENTING TO PARTICIPATE IN THE DRUG TRIAL AND NOT FALLING IN THE EXCLUSION CRITERIA WILL BE INCLUDED.

排除标准

  • 1-Patients having diabetes mellitus, malignant hypertension and other malignant disorders.
  • 2-Patient having Hypersensitivity, anorexia nervosa, history of Coronary artery disease, Congestive heart failure (CHF), arrhythmias, stroke, cardiac disorders, and those receiving Mono amino oxidase inhibitors (MAOIs ) etc.
  • 3-Pregnant and lactating mothers.
  • 4-Patients having any hormonal disturbances like hypothyroidism.
  • 5-Patients not complying with the directions of the physician.
  • 6-BMI > 40 kg/m2 7-Patient with major complications and in requirement of emergency treatment.

结局指标

主要结局

patients of both sexes between age group 18 to 60 years of medoroga will be selected for relieving sign and symptoms

时间窗: 4 weeks.

次要结局

  • Asses the comparative efficacy between Tryushanadi Guggulu and Navaka Guggulu in case of medoroga.(4 weeks)

研究者

发起方
NATIONAL INSTITUTE OF AYURVEDA JAIPUR
申办方类型
Research institution and hospital

研究点 (1)

Loading locations...

相似试验